World

Two new Ebola vaccines to join DR Congo clinical trial

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/11/2026, 11:47:25 UTC.

Briefings

Two new Ebola vaccine candidates are being added to a clinical trial in the Democratic Republic of the Congo (DRC) as the country continues to battle a deadly outbreak caused by the Bundibugyo species of the virus. The evidence indicates these vaccines are being evaluated alongside existing candidates within the same trial structure. No specific efficacy rates, patient numbers, or timeline completions are provided in the source text.

Key points

• Two new Ebola vaccine candidates are being added to a clinical trial in the Democratic Republic of the Congo (DRC) as the country continues to battle a deadly outbreak caused by the Bundibugyo species of the virus.

Context

The Democratic Republic of the Congo is currently experiencing a severe Ebola outbreak involving the Bundibugyo species of the virus, prompting the addition of new vaccine candidates to an ongoing clinical trial.

Limitations

The source evidence does not specify the number of participants, the duration of the trial, the specific efficacy rates, or the completion date of the vaccine candidates.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/11/2026, 13:48:21 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiebnpyutvac3v4g2bse33iwzv27q6bhng4b5gcighslu3e2nmxp2y